Technology major Microsoft has partnered with Adaptive Biotechnologies to map the genetics of the human immune system, to improve diagnoses of cancers and other diseases.
Adaptive Biotechnologies is a genomics and technology company working to map the genetics of the immune system.
The immune system is nature’s most finely-tuned diagnostic as it routinely scans and reads any signal of disease – such as a cancer cell or an infectious agent – in the body, and holds the genetic code that can give insights into detecting these diseases.
The companies hope to pair advances in AI and machine learning with recent breakthroughs in biotechnology to map out the immune system and tap into the body’s impressive diagnostic system.
The partnership will combine Adaptive’s immune sequencing technology with Microsoft’s research and large-scale machine learning and cloud computing capabilities.
The collaborators are planning to develop individual disease diagnostics at first, and then eventually develop a universal disease diagnostic from a single blood test.
As a part of the terms of the agreement, Microsoft has also made an unspecified financial investment into Adaptive.
“Partnering with Adaptive Technologies to decode the human immune system,” Satya Nadella, CEO, Microsoft said in a tweet.
The collaboration is a part of Microsoft’s Healthcare NExT initiative, launched in 2017 to maximize the ability of AI and cloud computing to accelerate innovation in the healthcare industry, advance science through technology, and turn the lifesaving potential of next discoveries into reality.